UAE First to Approve AstraZeneca’s Baxfendy for Hypertension

Post by : Bianca Suleiman

In a significant development, the Emirates Drug Establishment (EDE) has officially approved Baxfendy, a novel treatment by AstraZeneca aimed at patients grappling with uncontrolled high blood pressure.

With this landmark decision, the UAE claims the title of the first nation worldwide to sanction this medication, underscoring its commitment to enhancing access to advanced healthcare solutions and innovative cardiovascular therapies.

Baxfendy features the active ingredient baxdrostat and will be accessible in 1 mg and 2 mg dosages. This medication is intended for use alongside existing antihypertensive treatments for patients whose blood pressure remains elusive despite their current regime.

The drug functions by inhibiting an enzyme responsible for aldosterone production, a hormone closely associated with high blood pressure levels. By addressing the fundamental issue of resistant hypertension, Baxfendy provides a tailored treatment option for patients who find little efficacy in conventional therapies.

Dr. Fatima Al Kaabi, Director-General of the EDE, articulated that this approval is indicative of the UAE’s dedication to delivering advanced medical solutions, ensuring swift access to innovative drugs through adaptable regulatory frameworks.

She remarked that the EDE is consistently enhancing approval processes to align with national healthcare goals, thereby facilitating improved treatment outcomes and effective management of chronic conditions, particularly cardiovascular illnesses.

Sameh El Fangary, Gulf Country President at AstraZeneca, expressed his approval of the decision, noting that it broadens treatment avenues for hypertension patients and reinforces the faith in the empirical evidence supporting the drug.

He also reiterated the company's pledge to collaborate with healthcare entities in the UAE to promote patient access to pharmaceutical advancements and bolster long-term health outcomes.

The endorsement is grounded in encouraging results from two Phase III clinical trials, BaxHTN and Bax24, which demonstrated noteworthy reductions in blood pressure levels when Baxfendy was utilized in conjunction with standard therapies.

This regulatory approval aligns with the UAE’s broader ambition to fortify pharmaceutical security, enhance healthcare system efficiency, and secure sustainable access to groundbreaking treatments that bolster public health and community wellness.

#Global News #World News #UAE News #Emirates